Comprehensive Guide to Corticosteroid Pharmacology and Clinical Practice

Adrenal Gland Anatomy and Physiology

• Adrenal Gland Structure and Histology:

  • Capsule: The outermost protective layer.

  • Cortex: Comprises three distinct zones, each regulated differently and secreting specific hormones:

    • Zona Glomerulosa: The outermost cortical layer. It is regulated by Angiotensin II ($AII$) and Potassium ($K^+$). It secretes Mineralocorticoids, primarily Aldosterone.

    • Zona Fasciculata: The middle cortical layer. It is regulated by Adrenocorticotropic Hormone ($ACTH$). It secretes Glucocorticoids, specifically Cortisol and Corticosterone.

    • Zona Reticularis: The innermost cortical layer. It is regulated by $ACTH$ and other unknown factors. It secretes Adrenal Androgens, such as Dehydroepiandrosterone ($DHEA$) and $DHEA$-Sulfate.

  • Medulla: Contains Chromaffin cells, medullary veins, and splanchnic nerves. It secretes Catecholamines, specifically Epinephrine (Adrenaline) and Norepinephrine (Noradrenaline).

• Hypothalamic-Pituitary-Adrenal (HPA) Axis and Feedback Control:

  • Metabolism and stress responses are regulated via the HPA Axis.

  • Hypothalamus: Secretes Corticotropin-Releasing Hormone ($CRH$).

  • Anterior Pituitary: Receives $CRH$ and secretes $ACTH$.

  • Adrenal Cortex: Receives $ACTH$ and secretes Cortisol.

  • Feedback Mechanism: Cortisol exerts negative feedback on both the Hypothalamus and the Anterior Pituitary to regulate its own production.

  • Stress Response: Physical or emotional stress triggers the release of Cortisol (metabolic regulation) and Adrenaline (rapid increase in Heart Rate ($HR$), Blood Pressure ($BP$), and Glucose).

Classification and Comparative Potency of Corticosteroid Drugs

• Natural Actions:

  • Glucocorticoid Action: Widespread effects on carbohydrate and protein metabolism; potent anti-inflammatory and immunosuppressive properties (e.g., Cortisol).

  • Mineralocorticoid Action: Regulation of water and electrolyte balance (e.g., Aldosterone).

  • Therapeutic Goal: Except for replacement therapy, drugs are primarily used for anti-inflammatory and immunosuppressive effects. Metabolic actions are typically viewed as unwanted side effects.

• Comparative Potency Table:

  • Short-acting (Half-life: $8-12$ hours):

    • Hydrocortisone (Cortisol): Relative Glucocorticoid Potency = $1$; Relative Mineralocorticoid Potency = $1$. It is the main human hormone and the drug of choice for replacement therapy.

    • Fludrocortisone: Relative Glucocorticoid Potency = $10$; Relative Mineralocorticoid Potency = $12.5$. It is the drug of choice for mineralocorticoid effects.

  • Intermediate-acting (Half-life: $12-36$ hours):

    • Prednisolone: Relative Glucocorticoid Potency = $4$; Relative Mineralocorticoid Potency = $0.8$. Drug of choice for systemic anti-inflammatory/immunosuppressive effects.

    • Methylprednisolone: Relative Glucocorticoid Potency = $5$; Relative Mineralocorticoid Potency = $0.5$.

  • Long-acting (Half-life: $36-72$ hours):

    • Betamethasone: Relative Glucocorticoid Potency = $25$; Relative Mineralocorticoid Potency = Negligible. Used when water retention must be avoided.

    • Dexamethasone: Relative Glucocorticoid Potency = $25$; Relative Mineralocorticoid Potency = Minimal.

Mechanism of Action

• Cellular Signaling Pathway:

  1. Steroids (e.g., Cortisol) travel in the blood bound to Corticosteroid-binding globulin (CBG) and enter the target cell as free molecules.

  2. Binding: The steroid enters the cytoplasm and binds to an intracellular receptor ($R$). This receptor is initially bound to stabilizing proteins, including two molecules of heat-shock protein 90 ($hsp90$) and factors like $FKBP5$ (denoted as $\text{X}$).

  3. Activation: Binding causes receptor-protein dissociation (release of $hsp90$ and associated molecules).

  4. Dimerization: Two receptor-steroid complexes dimerize.

  5. Nuclear Entry: The dimer enters the nucleus.

  6. Transcriptional Regulation: The dimer binds to Glucocorticoid Response Elements (GRE) on the regulatory region of the gene. It regulates transcription via RNA polymerase $II$ and associated transcription factors (coactivators or corepressors).

  7. Protein Production: The resulting mRNA is edited, exported to the cytoplasm, and translated into proteins that mediate the final hormone response.

• Receptor Types:

  • Mineralocorticoid Receptors (MR): High affinity (occupied most of the time); expressed in specific tissues like the kidney, heart, colon, and hippocampus.

  • Glucocorticoid Receptors (GR): Low affinity (activated only by high levels, such as the morning peak or during stress); expressed ubiquitously.

  • Temporal Aspect: Due to the gene-transcription mechanism, some effects take hours to days to manifest.

Physiological and Pathological Actions of Glucocorticoids

• 1. Metabolic Actions:

  • Carbohydrates: Decreased glucose uptake/utilization and increased gluconeogenesis, resulting in hyperglycemia.

  • Proteins: Increased catabolism and reduced anabolism (leads to muscle wasting).

  • Lipids: Permissive effect on lipolytic hormones and redistribution of fat (leads to moon face, buffalo hump).

  • Purpose: Provides energy to combat stress (trauma, infection, bleeding, etc.).

• 2. Anti-inflammatory Actions:

  • Broad Scope: Inhibits early stages (redness, heat, pain, swelling) and late stages (wound healing, repair, proliferative chronic reactions).

  • Molecular Mechanism:

    • Increases anti-inflammatory mediators (e.g., Annexin 1 or Lipocortin 1), which inhibits Phospholipase $A_2$ in the arachidonic acid pathway.

    • Decreases pro-inflammatory cytokines/proteins: $TNF$, $IL-1$, $IL-2$, $IL-6$, Cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase.

    • Decreases histamine release from mast cells.

  • Hematological Effects: After a single dose, circulating neutrophils increase, while lymphocytes, eosinophils, and basophils decrease.

• 3. Immunosuppressive Actions:

  • Suppresses T-lymphocytes and cytokine production.

  • Suppresses B-lymphocytes (dampens humoral immunity).

  • Reduces plasma concentrations of complement components.

  • Enhances destruction of lymphoid cells (T-cells more sensitive than B-cells; lytic effects are marked in malignant lymphatic cells).

• 4. Other Actions:

  • Fetal Lungs: Promotes maturation.

  • Calcium and Bone: Pathologically inhibits intestinal absorption and enhances renal excretion of calcium. Reduces osteoblast function and increases osteoclast function, causing bone matrix loss.

  • Stomach: Increases secretion of gastric acid and pepsin.

Mineralocorticoid Actions

• Mechanism in the Kidney: Aldosterone acts on mineralocorticoid receptors in the distal tubules and collecting ducts.

• Primary Effects:

  • Reabsorption of Sodium ($Na^+$) and water.

  • Increased excretion of Potassium ($K^+$) and Hydrogen ions ($H^+$).

• Adverse Effects: Excessive action leads to hypertension and electrolyte imbalances.

Clinical Applications of Corticosteroids

• 1. Replacement Therapy: Used for adrenocortical insufficiency (e.g., Addison's disease, pituitary failure, or adrenal gland removal).

• 2. Anti-inflammatory Effects:

  • Respiratory: Asthma and Chronic Obstructive Pulmonary Disease (COPD).

  • Skin: Eczema, dermatitis.

  • Musculoskeletal: Arthritis, gout, bursitis.

  • Gastrointestinal: Inflammatory bowel disease (IBD).

• 3. Immunosuppressive Effects:

  • Prevention of organ transplant rejection.

  • Autoimmune disorders (Multiple Sclerosis, Myasthenia Gravis, Systemic Lupus Erythematosus).

  • Allergic reactions.

• 4. Malignancies: Treatment of leukemia and lymphomas; used as an antiemetic adjuvant and to reduce cerebral edema in tumors.

• 5. Obstetrics: Accelerating fetal lung maturation during contemplated premature birth.

Pharmacokinetics and Potency

• Administration Routes:

  • Oral: Rapid absorption from the GI tract.

  • Inhaled: Targeted delivery to lungs (e.g., Beclomethasone).

  • Topical: For conditions like atopic dermatitis. Potency rankings (UK):

    • Mild: Hydrocortisone.

    • Moderate: Betnovate-RD.

    • Potent: Beclomethasone $0.1\%$.

    • Very Potent: Dexamethasone.

• Factors Affecting Bioavailability and Duration:

  • Metabolism: Metabolized by $11\beta\text{-HSD2}$. Lower affinity for this enzyme leads to longer plasma half-life.

  • Receptor Affinity: Higher affinity for the GR provides stronger and longer effects.

  • Protein Binding: Approximately $90\%$ of cortisol is bound to plasma proteins (CBG and albumin). Binding reduces immediate effects but increases duration in the body.

  • Lipophilicity: High lipophilicity results in distribution to fat and less metabolism, extending the duration of action.

Adverse Effects and Cushing's Syndrome

• Major Side Effects:

  • Hyperglycemia (can precipitate diabetes).

  • Increased susceptibility to infections (e.g., fungal).

  • Peptic ulceration.

  • Osteoporosis and associated fractures.

  • Avascular necrosis of the head of the femur.

  • Muscular weakness (muscle wasting).

  • Growth retardation in children.

  • Hypertension (due to mineralocorticoid action).

  • Delayed wound healing.

  • Suppression of the HPA Axis.

  • Ocular effects: Glaucoma, cataracts.

  • Psychological effects: Euphoria, depression, emotional lability, or psychotic symptoms.

• Cushing’s Syndrome Clinical Manifestations:

  • Moon face with red (plethoric) cheeks.

  • Buffalo hump (fat deposit on the back of the neck).

  • Increased abdominal fat and easy bruising.

  • Thin skin, thin arms, and thin legs (muscle wasting).

  • Benign intracranial hypertension.

Inhaled Corticosteroids and Respiratory Management

• Examples: Beclomethasone, Budesonide, Fluticasone, Ciclesonide.

• Properties: High topical activity with low systemic activity.

• Therapeutic Actions:

  • Suppress bronchial inflammation.

  • Reduce exacerbations and retard disease progression.

  • Reverse tolerance to $\beta_2$ agonists.

• Unwanted Local Effects:

  • Oropharyngeal Candidiasis (thrush).

  • Hoarseness of voice.

• Prevention/Treatment of thrush: Use a spacer device, gargle/rinse mouth after use, or use topical antifungals.

Treatments for Allergic Disease and Anaphylaxis

• Management Strategies:

  • Allergen Avoidance: First-line (dust mites, food, pet dander).

  • Patient Education: Recognition of symptoms and use of adrenaline auto-injectors.

  • Pharmacotherapy:

    • Sodium Cromoglycate: Mast cell stabilizer. Blocks mast-cell degranulation and the release of inflammatory mediators (histamine, leukotrienes).

    • Omalizumab: Monoclonal antibody that binds to free Immunoglobulin E (IgE), preventing it from attaching to mast cells and basophils. Reduces high-affinity receptors and allergic inflammation.

    • Allergy Shots: Desensitization immunotherapy.

• Emergency Management of Anaphylaxis:

  • First-line Treatment: Intramuscular Adrenaline (Epinephrine).

  • Adrenaline Mechanisms:

    • $\alpha_1$ vascular smooth muscle: Causes vasoconstriction.

    • $\beta_1$ heart: Increases heart rate and force of contraction.

    • $\beta_2$ bronchial smooth muscle: Causes bronchodilation and inhibits mast cell activation.

  • Antihistamines: NOT recommended as first-line treatment; use only after stabilization (e.g., Cetirizine).

  • Corticosteroids: Routine use NOT advised in emergencies; reserved for refractory reactions or ongoing asthma/shock after initial resuscitation.

Questions & Discussion

• Q1: Which has the least mineralocorticoid action?

  • Answer: Betamethasone (Negligible activity).

• Q2: Preferred corticosteroid for replacement therapy in Addison's?

  • Answer: Hydrocortisone.

• Q3: Side effect primarily due to mineralocorticoid action?

  • Answer: Rise in blood pressure.

• Q4: Which is an inhalation corticosteroid?

  • Answer: Fluticasone.

• Q5: In which disorder are corticosteroids useful?

  • Answer: Inflammatory bowel disease.

• Q6: Drug of choice in anaphylaxis?

  • Answer: Adrenaline (intramuscular).

• Q7: Matching Unwanted Effects:

  • Suppression of T/B lymphocytes $\rightarrow$ Increased infections.

  • Breakdown of muscle protein $\rightarrow$ Muscle wasting/thinning of skin.

  • Stimulation of gluconeogenesis $\rightarrow$ Hyperglycemia.

  • Gastric acid secretion $\rightarrow$ Peptic ulceration.

  • Lipolysis/fat redistribution $\rightarrow$ Moon face/buffalo hump.

  • Reduced calcium absorption $\rightarrow$ Osteoporosis.

• Case Study Note (Ryan): Ryan was using a SABA (Short-Acting Beta Agonist/Salbutamol) more than expected and was not using his "brown inhaler" (Beclomethasone) consistently. His parents were concerned about growth retardation.

• Reducing Adverse Effects:

  1. Use inhalational/topical delivery (localized).

  2. Use the least potent steroid possible.

  3. Use the lowest effective dose.

  4. Use for the shortest duration possible.

  5. Single morning dose: Administering once in the morning mimics the natural circadian cortisol rhythm, causes less HPA axis suppression, and reduces adrenal suppression compared to divided doses.